Results 251 to 260 of about 334,676 (308)

An orthoflavivirus inhibitor targeting multifunctional NS2A protein, a previously unidentified target. [PDF]

PLoS Pathog
Borrenberghs D, Chan KWK, Van Brandt S, Jaensch S, Choy MMJ, Geluykens P, Bouayadi AE, Lauwers D, Bist P, Stoops B, Van de Ven J, Vermeulen P, Megens S, Thys K, Peeters D, Kaptein SJF, Neyts J, Vasudevan SG, Koul A, Goethals O.   +19 more
europepmc   +1 more source

Challenges facing long-acting PrEP implementation in large populations. [PDF]

Emerg Microbes Infect
Sun C, Liao Y.
europepmc   +1 more source

Immune Remodeling in People Living with HIV/HBV Co-Infection on Long-Term Therapy: Revisiting the Paradigm of Additive Dysfunction [Letter]. [PDF]

Infect Drug Resist
Peppa D, Alrubayyi A, Bhagani S.
europepmc   +1 more source

Tracking the evolution of multiple in vitro HCV replicon mutants under protease inhibitor selection pressure by 454 ultra deep sequencing. [PDF]

Fanning, G, Verbinnen, T, Neyts, Johan, Vandenbroucke, I, Simmen, K, Vijgen, L, Van Marck, H, Claes, Marijke, Lenz, O   +8 more
core  

Some of the next articles are maybe not open access.

Related searches:

Genotypic antiretroviral drug resistance testing at low viral loads in the UK

HIV Medicine, 2008
BackgroundAntiretroviral drug resistance testing is recommended in HIV‐1 infected patients failing therapy in order to inform treatment selection. Although guidelines and test manufacturers recommend a viral load of at least 500–1000 HIV‐1 RNA copies/mL for genotypic resistance testing to be performed, prompt management of virological failure could ...
P A Cane, Erasmus Smit, S Kirk
exaly   +5 more sources